Glecaprevir coformulated with pibrentasvir (G/P) is approved to treat hepatitis C virus (HCV) infection and was highly efficacious in phase 2 and 3 studies. Treating HCV genotype (GT) 3 infection remains a priority, as these patients are harder to cure and at a greater risk for liver steatosis, fibrosis progression and hepatocellular carcinoma. Data were pooled from five phase 2 or 3 trials that evaluated 8-, 12-and 16-week G/P in patients with chronic HCV GT3 infection. Patients without cirrhosis or with compensated cirrhosis were either treatment-naïve or experienced with
| INTRODUC TI ON
Hepatitis C virus (HCV) genotype (GT) 3 is the second most prevalent GT worldwide, responsible for approximately 25-30% of an estimated 71-80 million HCV infections.
1,2 Direct-acting antiviral (DAA) therapies have replaced pegylated interferon (pegIFN) plus ribavirin (RBV) as the standard-of-care treatment for chronic HCV infection, 3 and demonstrate high rates of sustained virologic response at posttreatment week 12 (SVR12) in most HCV genotypes; however, these rates can be lower in subpopulations of patients with GT3 infection, particularly those with cirrhosis and/or prior HCV therapy. [4] [5] [6] [7] [8] [9] In addition to being more difficult to cure, HCV GT3 is associated with higher rates of liver steatosis, 10-12 a higher incidence of hepatocellular carcinoma than other HCV genotypes, 13 and is an independent predictor of fibrosis progression. 14, 15 Coformulated glecaprevir/pibrentasvir (G/P) is an approved treatment in countries including the United States, Canada, Europe, Australia and Japan, for all six major HCV GTs in patients without cirrhosis and with compensated cirrhosis. [16] [17] [18] Glecaprevir (GLE) and pibrentasvir (PIB) each have a high barrier to resistance, potent pangenotypic antiviral activity, 19, 20 primarily biliary metabolism and clearance, and negligible renal excretion. 21 In vitro, PIB maintains activity against GT3a NS5A single-position amino acid substitutions known to confer high degrees of resistance to earlier-generation NS5A inhibitors: M28T, A30K and Y93H, each of which confers less than 2.5-fold increase to the effective half-maximal concentration (EC 50 ) of PIB.
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Based on recent figures from the Polaris Observatory, treatmentnaïve patients without cirrhosis are projected to represent approximately 80% of patients with HCV infection, including those with
GT3
. 22 In addition, epidemiological evidence suggests that 50-65%
of people with GT3 infection are current or were former injection drug users, 4, 23, 24 a patient population that is implicated in driving emerging trends in the HCV epidemic. 25, 26 Currently, G/P is the only 8-week regimen recommended by both the American Association for the Study of Liver Diseases (AASLD) and the European Association of the Liver (EASL) treatment guidelines for treatment-naïve GT3-infected patients without cirrhosis 27, 28 ; this was based on a 95%
SVR at post-treatment week 12 (SVR12) rate in the phase 3 study, ENDURANCE-3.
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As mentioned above, HCV GT3-infected patients with concomitant cirrhosis and/or prior HCV treatment experience have historically been the most difficult patients to cure. [30] [31] [32] In the phase 3 study SURVEYOR-2 Part 3, 98% (39/40) of treatment-naïve patients with HCV GT3 infection and compensated cirrhosis achieved SVR12 after 12 weeks of G/P. 33 Based in part on these findings, AASLD
and EASL recommend 12 weeks of G/P for treatment-naïve patients with compensated cirrhosis. In SURVEYOR-2 Part 3, the SVR12 rates in treatment-experienced patients without cirrhosis treated for 12 and 16 weeks were 91% and 95%, respectively; the SVR12 rate in treatment-experienced patients with compensated cirrhosis treated for 16 weeks was 96%. 33 Based in part on these results, 16-week G/P is an alternative regimen per AASLD guidelines for patients with pegIFNbased treatment experience, irrespective of the presence of cirrhosis.
In this integrated analysis, data were pooled across five phase 2 or 3 trials that evaluated efficacy and safety of 8, 12 and 16 weeks of G/P in patients with chronic HCV GT3 infection, including those with compensated cirrhosis and/or prior treatment experience.
Patients were grouped by cirrhosis status, prior treatment experience and G/P treatment duration. Safety and SVR12 were analysed for each subgroup. (AEs) were attributed to G/P; AEs leading to study drug discontinuation were rare (<1%). G/P was well-tolerated and efficacious for patients with chronic HCV GT3 infection, regardless of cirrhosis status or prior treatment experience. Eight-and 12-week durations were efficacious for treatment-naïve patients without cirrhosis and with compensated cirrhosis, respectively; 16-week G/P was efficacious in patients with prior treatment experience irrespective of cirrhosis status.
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| Study oversight
All patients signed informed consent for their respective trial, and the original studies were conducted in accordance with the International Conference on Harmonization guidelines and the ethics set forth by the Declaration of Helsinki. All authors had access to all relevant study data, and reviewed and approved this manuscript for submission. 
| Study design

| Patient population
Eligibility criteria were generally the same between studies; Table S1 shows any discrepancies in eligibility criteria between phase 2 and phase 3 studies. 
| Endpoints
The endpoint of efficacy was described for the following GT3 subpopulations: treatment-naïve non cirrhotic (8 and 12 weeks G/P), treatmentnaïve cirrhotic (12 weeks G/P), treatment-experienced non cirrhotic (12 or 16 weeks G/P) and treatment-experienced cirrhotic (16 weeks G/P).
The endpoint of safety was described for the GT3 population overall and for the GT3 subpopulations of without cirrhosis and with cirrhosis, regardless of treatment duration or prior treatment experience. values below 80% and above 120% were considered non adherent).
| Other assessments
For resistance analyses, a polymorphism was defined as a baseline amino acid difference relative to the appropriate subtype-specific reference sequence. Regions encoding full-length NS3/4A or NS5A
were sequenced by next-generation sequencing from available baseline samples from all patients. Baseline polymorphisms were identified using a 15% detection threshold at amino acid positions 155, 156
and 168 in NS3 and 24, 28, 30, 31, 58, 92 and 93 in NS5A.
| Statistical analyses
Demographics, baseline characteristics and safety analyses were performed on the ITT population, which included all patients that
TA B L E 1 Baseline demographics and disease characteristics
Characteristic Male, n (%)
Treatment-naïve
Treatment-experienced
Without cirrhosis
Cirrhosis
Without cirrhosis
123 (59) 167 (57) 41 (59) 32 (65) 14 (64) 38 (75) Race, n (%) White 180 (87) 258 (88) 64 (93) 42 (86) 20 (91) 45 (88) Asian 14 (7) 20 (7) 2 (3) 7 (14) 2 (9) 4 (8) Black or African American 6 (3)
4 (1) 1 ( (84) 13 (59) 26 (51) SOF-based (16) 9 (41) 25 (49) History of injection drug use, n (%)
141 (68) 186 (63) 51 (74) 25 (51) 13 (59) 25 ( (18) 46 (16) 11 (16) 4 (8) 0
(4)
HCV GT3 subtype, n (%) 3a
206 (99) 291 (99) 68 (99) 48 (98) 20 (91) 50 (98)
1 (1) 1 (2) 1 (5) 1 (2) 3 g/i 38 (18) 31 (11) 1 ( 110 (37) 49 (71) 21 (43) 15 (68) 33 (65) Europe 99 (48) 108 (37) 5 (7) 6 (12) 1 (5) 2 (4) Rest of world 38 (18) 76 (26) 15 (22) 22 (45) 6 (27) 16 ( (18) 13/68 (19) 11/49 (22) 3/21 (14) 7/51 (14)
A30K
19 (9) 15 (5) 1 (1) 4 (8) 1 (5) 0
Y93H
10 (5) 14 (5) 5 (7) 4 (8)
BMI, body mass index; CKD, chronic kidney disease; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus.
a <12 months prior to screening; recent drug use data were not captured for patients enrolled in SURVEYOR-2. TA B L E 1 (Continued) received at least one dose of study drugs. Efficacy analyses were performed on the ITT and mITT populations. For the primary efficacy endpoint (SVR12), a two-sided 95% confidence interval (CI) was calculated using the normal approximation to the binomial distribution. Subgroup efficacy analyses of SVR12 (including stratification by race, fibrosis score, whether receiving opioid substitution therapy, history of drug use and baseline polymorphisms in NS3 and NS5A)
were performed on the mITT population. For the GT3 subpopulation of treatment-naïve or treatment-experienced patients without cirrhosis, the difference in the rate of relapse between treatment durations was calculated with a 95% confidence score interval. For the GT3 subpopulation of treatment-naïve patients without cirrhosis (8 and 12 weeks), treatment duration was compared within subgroups using Fisher's exact test.
| RE SULTS
| Baseline characteristics and demographics
Among 693 patients with HCV GT3 infection, the majority (72%; 502/693) had no prior history of HCV treatment and were without cirrhosis; these patients were treated with either 8 weeks (n = 208) or 12 weeks (n = 294) of G/P (Table 1) . Sixty-nine treatment-naïve patients with compensated cirrhosis received G/P for 12 weeks. population, which includes all patients who received at least one dose of study drug, and (B) modified ITT population, which excludes those patients in the ITT population with premature discontinuation, loss to follow-up or nonadherence to the study drug. For SVR12 rates less than 100%, confidence intervals were calculated at 95% using the normal approximation to the binomial distribution. Tx, treatment; exp, experienced; wks, weeks, SVR12, sustained virologic response at post-treatment week 12; G/P, glecaprevir and pibrentasvir (Table S2 ). Of these, five patients with virologic failure (three with on-treatment virologic failure and two with relapse) were excluded for non adherence to study drug.
| Efficacy
Using the same mITT analytical approach described above, efficacy in treatment-naïve patients without cirrhosis was analysed by key patient subgroups, comparing the SVR12 rates between those treated with 8 versus 12 weeks of G/P (Table 3) . Across all patient subgroups, there were no statistically significant differences in SVR12 rates analysed by treatment duration, including fibrosis stage, baseline HCV RNA and the presence of baseline NS5A polymorphisms.
| Resistance
Baseline polymorphisms in NS3 at amino acid positions of interest were rare, and those in NS5A were variably detected (14% to 29%) across the different GT3 cohorts. The baseline prevalence of NS5A-Y93H and NS5A-A30K in treatment-naïve patients without cirrhosis treated for 8 weeks was 5% and 9%, respectively (Table 1 ).
Among treatment-naive patients without cirrhosis with baseline A30K or Y93H, there were no statistically significant differences in SVR12 rates between the 8-and 12-week durations (Table 3) ; the mITT SVR12 rates for patients with baseline Y93H treated for 8 and (Table 4) . Overall, in treatment-experienced patients without cirrhosis treated for 12 weeks, the baseline prevalence of NS5A-A30K and NS5A-Y93H was 8% each; the baseline prevalence of NS5A-A30K and NS5A-Y93H in treatment-experienced patients treated for 16 weeks was 5% and 0% (in those without cirrhosis) and 0% and 2% (in those with cirrhosis), respectively (Table 1) . Treatmentemergent NS3 substitutions Y56H, Q80K/R, A156G or Q168L/R were observed in 12 of the patients with virologic failure (Table 4) .
Treatment-emergent NS5A substitutions S24F, M28G/K, A30G/K, L31F or Y93H were detected in 15 patients; the most common substitutions were the linked A30K + Y93H substitutions in NS5A detected in 10 patients at the time of failure (Table 4) .
| Adverse events and laboratory abnormalities
Across all patients, adverse events (AEs) occurring in ≥10% of patients were headache, fatigue and nausea (Table 5 ). Rates of study drug discontinuation due to AEs (0.4%) were low. Serious AEs occurred in 3% of patients, none of which were considered related to study drugs by investigators. Across all patients, grade 3 or higher laboratory abnormalities in alanine aminotransferase (ALT), aspartate aminotransferase, total bilirubin or haemoglobin occurred in <1% of patients. There were two patients with grade 3 elevations in ALT and neither was associated with concomitant elevation in total bilirubin; these ALT elevations were not consistent with drug-induced liver injury. Four patients had grade 3 elevations in total bilirubin; these elevations had indirect predominance and occurred in patients with elevated bilirubin at baseline. The AE and laboratory abnormality profiles were similar between those with and without cirrhosis.
TA B L E 2 Reasons for non response
| D ISCUSS I ON
Patients with HCV GT3 are one of the more difficult-to-treat subpopulations of patients with chronic HCV infection. Moreover, epidemiological evidence suggests that a majority of people with GT3 infection are or were injection drug users. 4, 23, 24 The majority of injection drug users with HCV GT3 infection do not have cirrhosis and have never been treated for HCV infection; as a result, strategies to ensure access to effective HCV regimens for this population remain a priority. 25, 26 In this integrated analysis, we pooled data from 693 5%) treatment arms, the current analysis had limited power to detect a significant difference in SVR12 (mITT); thus, the impact of baseline A30K on efficacy of 8-week G/P was difficult to assess. These results support current HCV treatment guidelines, which recommend 8-week G/P treatment without the need for baseline resistance testing in treatment-naïve, non cirrhotic patients, 27, 28 and suggest that G/P is highly effective regardless of past or ongoing injection drug use, or whether a patient is receiving opioid substitution therapy.
These findings could be particularly important for patients who inject drugs, as it has been suggested that reduced treatment duration can improve both treatment access and adherence. 34 Indeed, as increasingly safe and effective DAA-based therapies become available Detection of baseline polymorphisms and treatment-emergent substitutions was done with next-generation sequencing using a 15% detection threshold relative to subtype-specific reference sequence.
For samples with multiple variants (polymorphisms/substitutions) within a target, if individual variants were detected at ≥90% prevalence, they are considered to be linked and denoted by "+", whereas if one or more of the variants was detected at <90% prevalence, the variants are separated by a comma. Nonadherent to DAA and excluded from mITT analysis (as virologic failure unrelated to efficacy); additional details in Table S2 .
c Patient was infected with a GT3a virus at the time of virologic failure with viral sequences that were distinct from the sequences present at baseline and was determined to have been HCV reinfected.
to patients, nonadherence can be expected to emerge as the most important risk factor for treatment failure. 35 Alleviating the need for adherence to a long duration of treatment could help reduce the strain placed on both patient and provider resources and facilitate increased rates of cure in a population whose successful treatment is critical to reducing or eliminating global HCV burden. was not unexpected since the study population excluded patients with prior NS5A inhibitor treatment experience, and prevalence of these polymorphisms in patients who were never exposed to NS5A inhibitors is low. Moreover, the overall prevalence for A30K and Y93H in this study (6% and 5%, respectively) was consistent with the low prevalence of these polymorphisms in patients with HCV GT3 infection reported in previous studies (4.5-6% for A30K and 8.3-8.8% for Y93H). 31, 40, 41 In conclusion, SVR12 rates were high (≥95%) for patients with HCV GT3 infection treated with the label-recommended durations of G/P, and G/P was well tolerated in patients with or without cirrhosis. In treatment-naïve patients without cirrhosis, efficacy was high with 8 weeks of G/P treatment, and no patient or viral characteristic was associated with lower SVR12; importantly, extending the duration of treatment to 12 weeks did not provide any additional benefit to efficacy. The regimen of G/P for 16 weeks achieved high efficacy in treatment-experienced patients with or without cirrhosis, with the 12-week duration in treatment-experienced patients without cirrhosis being associated with a higher rate of relapse. The data from this integrated analysis support the label-recommended durations of 8 and 12 weeks of G/P for treatment-naïve patients without and with cirrhosis, respectively, and 16 weeks of G/P for treatment-experienced patients, regardless of cirrhosis status.
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